Heart failure in Europe: Guideline‐directed medical therapy use and decision making in chronic and acute, pre‐existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction – the ESC EORP Heart Failure III Registry
Top Cited Papers
Open Access
- 10 September 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 26 (12) , 2487-2501
Abstract
Aims: We analysed baseline characteristics and guideline‐directed medical therapy (GDMT) use and decisions in the European Society of Cardiology (ESC) Heart Failure (HF) III Registry. Methods and results: Between 1 November 2018 and 31 December 2020, 10 162 patients with acute HF (AHF, 39%, age 70 [62–79], 36% women) or outpatient visit for HF (61%, age 66 [58–75], 33% women), with HF with reduced (HFrEF, 57%), mildly reduced (HFmrEF, 17%) or preserved (HFpEF, 26%) ejection fraction were enrolled from 220 centres in 41 European or ESC‐affiliated countries. With AHF, 97% were hospitalized, 2.2% received intravenous treatment in the emergency department, and 0.9% received intravenous treatment in an outpatient clinic. AHF was seen by most by a general cardiologist (51%) and outpatient HF most by a HF specialist (48%). A majority had been hospitalized for HF before, but 26% of AHF and 6.1% of outpatient HF had de novo HF. Baseline use, initiation and discontinuation of GDMT varied according to AHF versus outpatient HF, de novo versus pre‐existing HF, and by ejection fraction. After the AHF event or outpatient HF visit, use of any renin–angiotensin system inhibitor, angiotensin receptor–neprilysin inhibitor, beta‐blocker, mineralocorticoid receptor antagonist and loop diuretics was 89%, 29%, 92%, 78%, and 85% in HFrEF; 89%, 9.7%, 90%, 64%, and 81% in HFmrEF; and 77%, 3.1%, 80%, 48%, and 80% in HFpEF. Conclusion: Use and initiation of GDMT was high in cardiology centres in Europe, compared to previous reports from cohorts and registries including more primary care and general medicine and regions more local or outside of Europe and ESC‐affiliated countries.Keywords
Funding Information
- Abbott Fund
- Amgen Foundation
- AstraZeneca
- Bayer
- Boehringer Ingelheim España
- Bristol Myers Squibb Foundation
- Daiichi Sankyo Europe
- Edwards Lifesciences
- Novartis
- Servier
- Vifor Pharma
This publication has 55 references indexed in Scilit:
- Reversals in the Decline of Heart Failure Mortality in the US, 1999 to 2021JAMA Cardiology, 2024
- Impact Analysis of Heart Failure Across European Countries: An ESC-HFA Position PaperESC Heart Failure, 2022
- Therapeutic Inertia in the Pharmacological Management of Heart Failure with Reduced Ejection FractionESC Heart Failure, 2022
- Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart FailureEuropean Journal of Heart Failure, 2021
- Implementation of Sacubitril/Valsartan in Sweden: Clinical Characteristics, Titration Patterns, and DeterminantsESC Heart Failure, 2020
- Association Between Aging of the US Population and Heart Disease Mortality From 2011 to 2017JAMA Cardiology, 2019
- Factors Associated with Underuse of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction: An Analysis of 11 215 Patients from the Swedish Heart Failure RegistryEuropean Journal of Heart Failure, 2018
- Is Hyperkalaemia in Heart Failure a Risk Factor or a Risk Marker? Implications for renin–Angiotensin–Aldosterone System Inhibitor UseEuropean Journal of Heart Failure, 2018
- Heart Failure with Mid-Range Ejection Fraction in CHARM: Characteristics, Outcomes and Effect of Candesartan Across the Entire Ejection Fraction SpectrumEuropean Journal of Heart Failure, 2018
- Adherence to Heart Failure Quality-of-Care Indicators in US HospitalsArchives of internal medicine (1960), 2005